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1 nuclease dead Cas9 (dCas9) mutant for transcriptional activation (VP64, MS2:p65:HSF1, and 2 p300 fusions) [3, 4] and repression (KRAB fusion) [5] by directly fusing the heterologous 3 domains to dCas9 or localizing them using the MS2 RNA binding protein in conjunction with a 4 modified gRNA architecture containing MS2 binding sites.
5
The ability to deliver multiple gRNAs simultaneously makes our CRISPR/Cas9 system 6 highly amenable to multiplex genome editing. Previously, this has been achieved by delivering 7 multiple plasmids encoding gRNAs expressed from the strong U6 pol III promoter targeting 8 several different genes. However, this becomes troublesome due to poor efficiency and 9 toxicity associated with the delivery of large amounts of DNA plasmids to cells. An alternative 10 approach is to deliver the gRNAs as in vitro transcribed (IVT) RNAs [6] or chemically 11 synthesized RNA oligonucleotides [7] and Cas9 protein. However, for basic research this 12 approach becomes cost prohibited and is reserved for use in sensitive applications such as 13 gene editing of primary cell types, which do not tolerate transfection with 14 dsDNA/plasmids/expression plasmids. In light of this, a number of groups have generated 15 methods to clone multiple pol III promoter:gRNA elements into a single plasmid in tandem [8] 16 or alternating the orientation array format [9] . Although these methods are minimally 17 functional, there are drawbacks to these approaches. For instance, multiple groups have 18 raised the concern that numerous pol III promoters may engage in "Promoter Cross talk
19
Effects" and reduce the transcriptional activity of endogenous pol III driven genes, potentially 20 causing undesirable side effects [10] [11] [12] . Further, as these systems have largely been 21 validated via transient transfection, there may be a large amount of promoter interface when 22 stably integrated, as has been reported using arrays of pol II driven elements [13, 14] , 23 potentially limiting their utility for stable CRISPR/Cas9 mediated gene activation or repression.
24
Inspired by the endogenous CRISPR system, herein we describe methods for highly 25 efficient assembly and expression of CRISPR/Cas9 gRNA arrays using golden gate assembly 26 methods and pol II promoters [15] . We validated the system using gRNA array vectors 
21

Validation of guide RNAs
22
HEK293T cells were maintained in DMEM medium supplemented with 10% fetal bovine 23 serum (FBS). 1x10 5 cells of HEK293T cells were seeded in 24-well plate the day before Purification Kit (Thermo Scientific). Activity of the gRNAs was quantified by Surveyor 7 nuclease assay, gel electrophoresis, and densitometry as described [17] .
8
Vectors construction and LR clonase reactions 9
Plasmids containing the ccdB gene were maintained in One Shot® ccdB Survival™ 2 T1R 10 bacteria (Invitrogen). All enzymes used in this study were purchased from New England
11
BioLabs. All pENTR1 vectors were derived originally from pENTR221-GUS (Invitrogen). reaction with pDONR221 to generate pENTR221-MS2-p65-HSF1-T2A-eGFP, which was 23 subsequently used for LR Clonase reaction with pT3.5-CAG-DEST to generate pT3.5-CAG-1 Golden gate assembly of gRNA arrays 2 Single pGG vectors were generated using the same oligonucleotide ligation approach 3 described above. Primer sequences can be found in S1 Table. Arrays were then 4 generated using golden gate assembly. Briefly, 150 ng of each pGG-gRNA plasmid was 5 combined with 150 ng of the appropriate pACPT vector, followed by addition of 1uL of BsaI 6 (New England BioLabs), 1uL of T4 DNA Ligase and Buffer (New England BioLabs) and 7
water to a total of 20 uL. Golden gate assembly was then carried out using the following 
22
The complete mixture was incubated for 15 min before being added to cells in a drop wise 23 fashion. After 16 hours, the media was changed to fresh DMEM medium containing 10% Surveyor assays were performed as previously descried [17] . Briefly, after electroporation 10 of CRISPR/Cas9 plasmids and incubation for 3 days genomic DNA was extracted using using Image J software as described [2] .
23
Q-RT-PCR analysis 24
Taq-man quantitative PCR was performed with following primer and probes; ASCL1; 
5
Golden gate assembly of gRNA arrays with up to 10 gRNAs 6
To simplify the generation of gRNA arrays we utilized the golden gate cloning system [15].
7
We used type IIS restriction enzyme sites (BsmBI) and over hangs previously published 8 and validated for robust golden gate assembly of TALEN DNA binding domains [18] . We 9 then designed and assembled cassettes for oligonucleotide ligation of protospacer 10 sequences using a different type IIS restriction enzyme (BsaI) flanking a stuffer sequence.
11
In addition, we included a Csy4 ribonuclease target sequence directly upstream of the 12 target gRNA sequences such that after golden gate assembly each gRNA is directly flanked 13 by the Csy4 target sequence (Fig. 1a) . Next, we designed a gRNA array acceptor plasmid 14 (pACPT) containing a LacZ gene, for blue/white colony selection after golden gate 15 assembly, flanked by appropriate BsmBI sites and an upstream U6 pol II promoter to drive 16 expression of assembled gRNA arrays (Fig. 1a) . We also included a terminal Csy4 target 17 sequence, such that the last gRNA is free of additional sequence when processed, and a 18 poly T termination sequence. In order to produce a highly modular system for rapid and 19 efficient cloning of the U6 driven gRNA array cassettes, attL1/2 sequences were included in 20 pACPT for Gateway cloning (Fig. 1a) . We have termed this set of plasmids for 21 oligonucleotide ligation pGG1-10 and the acceptor plasmids pACPT1-10 ( Fig. 1b) . An
22
example of the plasmids required for golden gate assembly of a 4 gRNA array and the 23 structure of the final expression plasmid are shown in Fig. 1c .
24
In order to validate our golden gate assembly system we ligated oligonucleotides 25 encoding protospacer sequences targeting 10 genes we previously validated for 26 CRISPR/Cas9 mediated DSB induction with an average editing frequency of ~22% and a 1 range of 10-35% (1:GOSR1, 2:PPP2R2A, 3:CNTFR, 4:DMD, 5:ZBTB10, 6:KAT7, 7:SPPL3, 2 8:CCM2, 9:PRDX1, 10:TRIP12; S1 Fig. 1) . We then performed golden gate assembly of 3 arrays containing 3, 5, 7, or 10 of these gRNAs and validated the resultant plasmids by 4 Sanger sequencing (S2 Fig. 2) . As with the previously described golden gate assembly 5 system, we observed sufficient white bacterial colonies upon X-gal staining and all white 6 colonies sequenced as expected. These data demonstrate that we have developed a highly 7 functional platform for the generation of gRNA arrays using our golden gate cloning 8 platform.
9
Assessment of gene editing frequencies using gRNA arrays
10
In order to validate the functionality of our assembled gRNA arrays, we transfected
11
HEK293T cells with gRNA arrays containing 3, 5, 7, or 10 gRNAs and a plasmid expressing
12
Cas9 alone or Cas9 linked via a P2A element to the human codon optimized Csy4 13 ribonuclease [19] ( Fig. 2a) . Notably, we observed negligible editing without expression of editing was again observed with the 9 th and 10 th gRNA (Fig. 2b) .
19
Interestingly, two previous reports using 2 or 4 gRNA arrays differed in the length of flanked 20
Csy4 target sites used, 20bp or 28bp [20, 21] . The larger 28bp Csy4 sequence contains a 21 'handle' region of 8bp that may be important for Csy4 processing 19 . However, there is no 22 clear evidence demonstrating which flanking Csy4 target sequence is superior for optimal 23 Csy4 processing. Thus, we generated an additional set of pGG1-10 and pACPT plasmids 24 harboring the 28bp Csy4 target site and again assembled the 10 gRNA array expressed via 25 the U6 pol III promoter. The gRNA array containing the 20bp Csy4 site produced slightly 1 higher levels of gene editing at all 10 target sites, indicating the 20bp Csy4 site may be 2 more efficiently cleaved by Csy4 than the 28bp sequence ( Fig. 2b) . However, we still 3 observed low editing over all and nearly undetectable editing at gRNA 7 and 8. This While a 20bp Csy4 cleavage site leads to slightly higher gene editing frequencies than a 10 28bp site, the gene editing frequencies are lower than individual U6-gRNA editing overall.
11
We hypothesized that the use of the canonical U6 driven expression of the highly repetitive 12 array may produce a very unstable transcript due to the lack of a polyA tract and G cap 13 associated with pol III driven genes. Thus, in order to stabilize the gRNA array transcript,
14
we removed the U6 promoter from the pACPT1-10 plasmids (S5 Fig. 5 ) and again 15 assembled an array of 10 gRNAs that were subsequently cloned into a vector containing 16 the strong pol II CMV promoter with a poly adenylation sequence (Fig. 3a) . The array was 17 transfected into HEK293T and demonstrated improved gene editing frequencies overall,
18
with ~10%-21% gene editing across all gRNA targets, albeit still at lower frequencies than 19 individual U6-gRNA editing (Fig. 3b , green line vs blue dots). We then tested the 10 gRNA 20 array expressed from the very strong intron containing pol II CAG promoter with a poly 21 adenylation sequence (Fig. 3a) . Surprisingly, we found the rates of gene editing using the 22 CAG promoter were significantly higher than the individual U6-gRNA editing, with only 3 23 gRNA target sites having slightly lower editing when expressed in CAG driven array ( Fig.   24 3b, purple line, p < 0.001 ). We further tested the effect of the promoter driving the One of the motivations for the development of a robust gRNA array system is to avoid the 7 toxicity and low transfection efficiency associated with delivery of numerous U6-gRNA 8 containing plasmids. Thus, we wanted to test our gRNA array plasmids against with 9 standard multiplexed plasmid delivery. We first attempted to deliver 10 individual U6-gRNA 10 plasmids along with a Cas9 expressing plasmid using 250 ng of each plasmid as we did 11 with our gRNA array and Csy4/Cas9 vector (Fig. 4a) . However, this produced substantial In order to allow for multiplex gene activation using gRNA arrays, we generated a set of 
26
We used this system to generate a gRNA activation array containing 5 previously validated 1 gRNAs used for gene activation [3] (Fig. 5a) . We then transfected HEK293T cells with 2 individual U6-MS2-gRNAs, dCas9-VP64 and MS2:p65:HSF1 plasmids to assess standard 3 gene activation with the SAM system using individual U6 gRNAs (Fig. 5b) . These activation 4 results were then compared with gene activation in cells transfected with the MS2 gRNA 5 array, Csy4/dCas9-VP64 and MS2:HSF1:p65 plasmids. We observed robust levels of gene 6 activation and, therefore these results demonstrate that MS2 gRNA arrays are amenable to 7 multiplex gene activation.
DISCUSSION
9
We report the development and methods for assembly of CRISRP/Cas9 gRNA arrays 
16
One of the more unexpected results of our study was that the use of the pol II CAG 17 promoter optimally expressed the gRNA array, in that it resulted in higher gene editing 18 frequencies compared to individual U6-gRNAs plasmids, which is the most commonly used 19 format of the CRISPR/Cas9 system. This is unexpected as the U6 promoter has been 20 shown to be highly efficient at transcription of gRNAs with nearly a log fold higher 21 expression compared to CMV for instance [19] . Although the CAG promoter may simply 22 produce larger amounts of transcript compared to the standard U6 promoter, another 23 potential reason for enhanced editing may be due to the use the Csy4 enzyme. Perhaps
24
Csy4 protects the gRNA from degradation that normally occurs from endogenous non-25 specific RNases, providing a larger window of time for Cas9 to bind the gRNA and induce 1 targeted DSBs. Alternatively, Csy4 may directly interact with Cas9 to enhance gRNA 2 loading after gRNA array processing. Future studies investigating the mechanism of Csy4 3 array processing and conceivable interaction with Cas9 will be required to identify any 4 potential mechanism of enhancement of the system.
5
Since its discovery the CRISPR/Cas9 system has been rapidly adopted for 6 numerous applications due to its ease of use, specificity, and the seemingly limitless ability 22, 23] and at maximum 7 gRNAs were actually used in the 16 experiments [8, 21] . As this field progresses to generate more sophisticated genetic circuits 17 the requirement to express more gRNAs will also likely increase.
18
Although we developed a gRNA array platform for spCas9 using standard and MS2 
7
Finally, a very exciting aspect of the gRNA array technology is the ability to use in 8 vitro transcribed RNA encoding the gRNA array. This approach may be especially desirable 9
for multiplexed editing of primary human lymphocytes, such as T cells. It is well documented 10 that plasmid DNA is highly toxic to primary lymphocytes [24] and thus the use of IVT gRNA 11 arrays may allow for highly efficient multiplex gene editing of primary human cell types for 12 research and therapy. Indeed, we were able to generate and test IVT gRNA array in primary 13 human T cells combined with mRNA encoding Csy4 and Cas9. However, we observed no 14 detectable gene editing using this approach in primary human T cells (data not shown). This 15 negative result may be due to a timing issue as the gRNA array is perhaps largely degraded 16 by the time active Cas9 and Csy4 protein become abundant in the cells. This issue has 17 been recently described using single IVT gRNAs in T cells [7] . Perhaps the use of purified
18
Cas9 and Csy4 protein combined with IVT gRNA arrays will allow for highly multiplexed 19 editing of primary cell types. An alternative approach would be to deliver the entire system 20 with AAV6, which has been recently shown to be highly effective at delivering transient 
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The use of gRNA arrays for highly multiplexed genome engineering using the 
